SEHK:3692Pharmaceuticals
Assessing Hansoh Pharmaceutical Group (SEHK:3692) Valuation After Earnings Growth And New XINYUE Indication Approval
What the latest earnings and drug news mean for Hansoh Pharmaceutical Group
The latest move in Hansoh Pharmaceutical Group (SEHK:3692) is being shaped by two fresh developments: full year 2025 earnings and new regulatory progress for its autoimmune drug XINYUE in China.
For the year ended 31 December 2025, Hansoh Pharmaceutical Group reported sales of CN¥15,028.32 million, compared with CN¥12,260.81 million a year earlier, and net income of CN¥5,555.46 million versus CN¥4,371.83...